Cholangiocarcinoma Clinical Trials in New Haven, Connecticut
4 recruitingNew Haven, Connecticut
Showing 1–4 of 4 trials
Recruiting
Phase 2
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 2
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled7 locationsNCT07169734
Recruiting
Not Applicable
The Dragon PLC Trial (DRAGON-PLC)
CholangiocarcinomaHepatocellular Carcinoma (HCC)Primary Liver Cancer
Maastricht University358 enrolled55 locationsNCT06914648